Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286060 | 1.00 | LATS1 (0.46) | LATS1SHMT2PIM2CHKAGSK3B | |
| SCHEMBL31145191 | 1.00 | LATS1 (0.46) | LATS1SHMT2PIM2CHKAGSK3B | |
| SCHEMBL31145183 | 1.00 | LATS1 (0.46) | LATS1SHMT2PIM2CHKAGSK3B | |
| SCHEMBL25244790 | 1.00 | LATS1 (0.46) | LATS1SHMT2PIM2CHKAGSK3B | |
| SCHEMBL31145249 | 1.00 | LATS1 (0.46) | LATS1SHMT2PIM2CHKAGSK3B | |
| SCHEMBL25286499 | 0.86 | LATS1 (0.42) | LATS1PIM2GSK3BROCK1HTR2C | |
| SCHEMBL25286498 | 0.86 | LATS1 (0.42) | LATS1PIM2GSK3BROCK1HTR2C | |
| SCHEMBL25290308 | 0.86 | LATS1 (0.42) | LATS1GSK3BROCK1HTR2CROCK2 | |
| SCHEMBL25249400 | 0.86 | LATS1 (0.42) | LATS1GSK3BROCK1HTR2CROCK2 | |
| SCHEMBL30417479 | 0.86 | LATS1 (0.42) | LATS1GSK3BROCK1HTR2CROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | MeiraGTx Gene Regulation Limited (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4448769-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | Meiragtx UK II Limited (GB) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111686-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | MEIRAGTX UK II LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | RNGTT, SLIRP, SNRPE | LATS1 3598/4885SHMT2 964/4885PIM2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.